Global Space Technologies partner Pfizer for vaccine awareness on DocExa platform
Pfizer, a major pharmaceutical company for incorporating downstream use of providing additional value added support within the specialty of Doctor e-consultation facilitation Tab.
Under this arrangement, Global Space team will leverage its Makebot stage for vaccine recognition and As a exceptional value proposition, Global space can also be establishing a digital Adult Vaccine appointment clinics on Docexa platform. This is only one of its kind initiative performed from the underserved adult Accreditation section. This stage would also supply a customized reservation beneath Doctor e-consultation Tab that is also hosted on Pfizer's customer microsite. This Tab is going to be redirected to a e-consultation page of Global Space that will display applicable physicians that are grownup vaccinators (HCPs current on DocExa stage ). Pfizer being engaged in the company inter alia of growing, manufacturing and marketing pharmaceutical and consumer health care products can help Global Space in expanding its market reach.
This will be a value added component on our present stage where it will facilitate sufferers to Enroll themselves for drug and DocExa will assign them to local authorized doctor. Being an integrated platform, it will immediately bring Pfizer's vaccine into the individual via a documented Doctor onto a single DocExa platform. The alliance could be a win-win for both DocExa and Pfizer because it'd be one of its type in carrying Healthcare especially vaccination program on a technology platform.
According to the new venture arrangement, Mr. Krishna Singh, Founder & CMD stated, 'We are Pleased to announce Presently, this venture is for a Single vaccine Nonetheless, it could be further extended Through all of the vaccines that Pfizer has in its portfolio and anticipated to establish new types in future. We're very This is the Significant breakthrough for our Business because we could enter into more and more such sort of partnership with other pharmaceutical firms going forward. This is very likely to provide us considerable growth impetus. Furthermore, This will improve our market reach as the Pfizer being a top pharmaceutical firm can help us in obtaining a greater number of patients and Physicians on our stage.'